Evidence map›Paper›PMID 37620322›Full record

ArticleNature communications2023

Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice.

Marta Isidro-Hernández, Ana Casado-García, Ninad Oak, Silvia Alemán-Arteaga, Belén Ruiz-Corzo, Jorge Martínez-Cano, Andrea Mayado, Elena G Sánchez, Oscar Blanco, Ma Luisa Gaspar and 14 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Childhood B cell leukemia: Intercepting the paths to progression.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024
    Review
  9. Article
  10. Article
  11. The evolving hematopoietic niche during development.Frontiers in molecular biosciences · 2024
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 2 countries.

Marta Isidro-Hernández *Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, Salamanca, Spain.ORCID http://orcid.org/0000-0001-8334-4981
Ana Casado-García *Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, Salamanca, Spain.
Ninad Oak *Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-9806-0217
Silvia Alemán-Arteaga *Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, Salamanca, Spain.ORCID http://orcid.org/0000-0002-9655-2242
Belén Ruiz-CorzoExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, Salamanca, Spain.
Jorge Martínez-CanoImmune system development and function Unit, Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas -Universidad Autónoma de Madrid), Madrid, Spain.ORCID http://orcid.org/0000-0001-6809-5489
Andrea MayadoInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Elena G SánchezDepartment of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain.
Oscar BlancoInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Ma Luisa GasparImmunobiology Department, Carlos III Health Institute, 28220, Majadahonda (Madrid), Spain.ORCID http://orcid.org/0000-0001-9858-3862
Alberto OrfaoInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.ORCID http://orcid.org/0000-0002-0007-7230
Diego Alonso-LópezBioinformatics Unit, Cancer Research Center (CSIC-USAL), Salamanca, Spain.ORCID http://orcid.org/0000-0003-1015-9923
Javier De Las RivasInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.ORCID http://orcid.org/0000-0002-0984-9946
Susana RiescoDepartment of Pediatrics, Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Salamanca, 37007, Spain.ORCID http://orcid.org/0000-0001-5443-8786
Pablo Prieto-MatosInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.ORCID http://orcid.org/0000-0003-2680-3285
África González-MurilloDepartment of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain.ORCID http://orcid.org/0000-0001-7747-1204
Francisco Javier García CriadoInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
María Begoña García CenadorInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Manuel Ramírez-OrellanaDepartment of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain.ORCID http://orcid.org/0000-0003-0332-6973
Belén de AndrésImmunobiology Department, Carlos III Health Institute, 28220, Majadahonda (Madrid), Spain.ORCID http://orcid.org/0000-0002-7391-2823
Carolina Vicente-Dueñas *Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. cvd@usal.es.ORCID http://orcid.org/0000-0002-5401-8295
César Cobaleda *Immune system development and function Unit, Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas -Universidad Autónoma de Madrid), Madrid, Spain. cesar.cobaleda@csic.es.ORCID http://orcid.org/0000-0003-3807-9204
Kim E Nichols *Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. Kim.Nichols@STJUDE.ORG.ORCID http://orcid.org/0000-0002-5581-6555
Isidro Sánchez-García *Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, Salamanca, Spain. isg@usal.es.ORCID http://orcid.org/0000-0001-6989-9905
Instituto de Investigación Biomédica de Salamanca · ESUniversidad de Salamanca · ESComplejo Hospitalario de Salamanca · ESHospital Infantil Universitario Niño Jesús · ESConsejo Superior de Investigaciones Científicas · ESInstituto de Salud Carlos III · ESSt. Jude Children's Research Hospital · USCentro de Investigación del Cáncer · ES

Funding

Pathogenesis of ETV6-Related Acute Lymphoblastic LeukemiaR01CA241452 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI NICHOLS, KIM ERIKA · 2020 to 2025
$2.6M
NCI NIH HHS R01 CA241452
6 · The paper itself

Abstract

The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5

Indexed as

Burkitt LymphomaLeukemiaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdaptor Proteins, Signal TransducingAnimalsImmunity, InnateMiceMyeloid Differentiation Factor 88Precursor Cells, B-LymphoidSignal TransductionAdaptor Proteins, Signal TransducingMyeloid Differentiation Factor 88

Identifiers

PMID37620322
PMCPMC10449887
OpenAlexW4386136742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.